$45 Million

Syros Pharmaceuticals Inc.

Underwritten Offering

Lead Left Bookrunner, December 2023

Syros Pharmaceuticals Inc.

Syros Pharmaceuticals, Inc. (The Company) (NASDAQ: SYRS) is a clinical-stage biopharmaceutical company developing targeted therapies for the frontline treatment of hematologic malignancies. Lead asset, tamibarotene, is a selective retinoic acid receptor alpha (RARα) agonist in a Phase III trial (SELECT-MDS-1) in combination with azacitidinein HR-MDS with RARαoverexpression and a Phase II trial (SELECT-AML-1) in combination with venetoclaxand azacitidinein newly diagnosed unfit AML with RARαoverexpression.